Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

NCT01231503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: GSK Biological's Investigational Malaria Vaccine 257049
BIOLOGICAL: Engerix-B
BIOLOGICAL: Tritanrix HepB Hib
BIOLOGICAL: BCG
BIOLOGICAL: OPV
BIOLOGICAL: Rouvax

Sponsor

GlaxoSmithKline

Collaborators

[object Object]